The optimal duration of oral anticoagulant therapy after a first episode of
venous thromboembolism (VTE) is still a matter of debate. It is essential
to balance the desired effect of the anticoagulants in reducing recurrences
against the risk of major bleeding. The aims of this paper are to describe
the current concepts in this field. Recent data, based on randomized contr
olled trials, suggest that it is necessary to tailor the duration of antico
agulation individually according to the topography of VTE and the presence
of risk factors. A 6-week treatment for patients with isolated calf vein th
rombosis is sufficient. For proximal thrombosis and/or pulmonary embolism,
a short anticoagulant course is sufficient in patients with temporary risk
factors (3 months), and a longer anticoagulant course (6 months at least) i
s recommended for cases with permanent risk factors or idiopathic VTE. For
these high-risk of recurrence patients, an assessment of low- or fixed-dose
oral anticoagulation is necessary in order to reduce the bleeding risk. It
is not possible to precisely determine the optimal duration with the avail
able data. We have already performed a metaanalysis on summary data that su
ggests a long course of oral anticoagulant therapy is superior to a short c
ourse. An individual meta-analytic approach is needed to draw more precise
conclusions on an interesting and important clinical topic. Blood Coagul Fi
brinolysis 11:701-707 (C) 2000 Lippincott Williams & Wilkins.